Aprea therapeutics, inc. APRE.US Overview
APRE AI Analysis & Strategy
Analysis Conclusion
The stock has a low value rating. If your investment strategy is value-oriented and you have long-term positions, it's crucial to adhere to your exit plan and consider reducing holdings.
APRE Current Performance
-4.00%
Aprea therapeutics, inc.
-1.19%
Avg of Sector
0.52%
S&P500
APRE Key Information
APRE Financial Forecast
Unit : USD
APRE Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -0.64 | - | -14.7% | 354.62K | - | 57.6% | -617.9% |
| 2024Q1 | -0.58 | - | -9.4% | 561.57K | - | 1,023.1% | -738.4% |
| 2023Q3 | -0.92 | - | 64.3% | 14.08K | - | -87.2% | -1,003.1% |
| 2023Q2 | -0.86 | - | -20.4% | 319.47K | - | 190.4% | -1,305.3% |
APRE Profile
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.